We are dedicated to bringing transformative therapies to patients – empowering them to embrace life to its fullest.
Our Story
Born out of the lab of Professor Patrick Gunning at the University of Toronto, a serial entrepreneur with a successful track record, HDAX Therapeutics was created with a foundation in translational science and a mission to advance revolutionary treatments.
Our entrepreneurial drug developers have built the technology behind HDAX from a mere concept into distinct programs with therapeutical potential in neurology, cardiometabolic diseases and more. HDAX is well-charged with an extensive network, profound passion and unwavering tenacity to transform therapeutic outcomes for patients.
Our Mission
HDAX exists to deliver meaningful medicines for patients.
We recognize the challenges with current HDAC6 targeting strategies, and are fundamentally reconceptualizing the way it is approached to unlock its full therapeutic potential and revolutionize patient outcomes.
Our values serve as our inspiration to excel in our endeavours and never lose sight of why our work matters – to change patients’ lives.
Innovation
Collaboration
Integrity
Our Team
HDAX has a unique blend of experienced leaders and passionate founders equipped with scientific background and business expertise to lead the future of precision HDAC6 targeting for diseases with high unmet needs.
